MINDACT (Microarray In Node negative Disease may Avoid ChemoTherapy) A prospective, randomised study comparing the 70-gene expression signature with common clinical-pathological criteria in selecting patients for adjuvant chemotherapy in node-negative breast cancer. (EORTC Protocol

In the last 20 years, little progress has been made with respect to assisting oncologists in treatment decision making for node-negative breast cancer patients. Great uncertainty persists in selecting those node-negative women who need adjuvant chemotherapy and those who could safely be spared this aggressive treatment. At present oncologists decide whether to prescribe chemotherapy based on common clinical and biological criteria (age, tumour grade, stage and hormone receptor expression). These criteria are used on the basis of guidelines such as the St Gallen and NIH consensus documents, or are organized into specific prognostic tools such as the Nottingham Prognostic Index or Adjuvant! Online.